Silco Pharmaceuticals Limited (DSE:SILCOPHL)

Market Cap	1.57B
Revenue (ttm)	428.63M
Net Income (ttm)	46.56M
Shares Out	103.81M
EPS (ttm)	0.45
PE Ratio	33.45
Forward PE	n/a
Dividend	0.10 (0.66%)
Ex-Dividend Date	Dec 9, 2024

Volume	739,029
Average Volume	1,023,297
Open	15.50
Previous Close	15.40
Day's Range	15.00 - 15.50
52-Week Range	12.60 - 23.90
Beta	0.27
RSI	54.83
Earnings Date	Nov 25, 2025

About Silco Pharmaceuticals

Silco Pharmaceuticals Limited engages in manufacturing and marketing of finished pharmaceutical products in Bangladesh and internationally. It offers products in the therapeutic areas of analgesic and antipyretic, anti-platelet, antiasthmatic, antibiotic, antidepressant, antidiabetic, antiemetic, antifungal, antihistamin, antihypertensive and antianginal, antimicrobial, antiprotozoal, antispasmodic, antiulcerant, anxiolytic, calcium and combinations, central muscle relaxants, diuretics, gastroprokinetic, haematinic, vitamins and minerals, laxat...

• Industry: Pharmaceutical Preparations
• Founded: 1995
• Employees: 313
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: SILCOPHL

Financial Performance

In 2024, Silco Pharmaceuticals's revenue was 410.10 million, a decrease of -11.75% compared to the previous year's 464.70 million. Earnings were 45.88 million, a decrease of -33.72%.